CGM, TIR and daily control
Recent social posts pushed continuous glucose monitors (CGMs) as personalization tools and advised cutting carbs and sugar while boosting activity, sleep and stress management to improve insulin sensitivity. The same conversations argued that time‑in‑range (TIR) and time‑below‑range (TBR) metrics give more actionable day‑to‑day signals than A1c for managing glucose. (x.com) (x.com)
A continuous glucose monitor is a wearable sensor that samples sugar in the fluid under the skin all day, turning glucose control into a live feed instead of a three-month average. (diabetes.org) The American Diabetes Association says glucose status can be assessed with hemoglobin A1c and with continuous glucose monitor measures including time in range, time above range, and time below range. Its 2025 standards say continuous glucose monitoring can show responses to meals, physical activity, and medication changes in day-to-day use. (diabetesjournals.org) Time in range means the share of the day a person stays in a target glucose band, usually 70 to 180 milligrams per deciliter for most adults with diabetes. The American Diabetes Association says many people with type 1 diabetes and type 2 diabetes should aim for at least 70% of readings in that range, or about 17 hours a day. (diabetes.org) Time below range is the flip side: minutes or hours spent under target, where the immediate risk is low blood sugar rather than a high average. The 2019 international consensus report on continuous glucose monitoring set common targets so clinicians and patients could compare daily patterns, not just averages. (diabetesjournals.org) Hemoglobin A1c still remains the main long-term marker in diabetes care because it estimates average glucose over roughly the previous three months. The American Diabetes Association says A1c does not capture daily highs and lows, which is why time in range adds detail rather than replacing the lab test. (diabetes.org) That difference can change everyday decisions. A person can post the same A1c while having very different swings after breakfast, workouts, missed sleep, or medication timing, and continuous glucose monitoring can make those patterns visible on the same day. (diabetesjournals.org) The push to use continuous glucose monitors as consumer tools widened in the United States on March 5, 2024, when the Food and Drug Administration cleared Dexcom Stelo as the first over-the-counter continuous glucose monitor. The agency said it is intended for adults 18 and older who do not use insulin, including people without diabetes who want to see how diet and exercise affect glucose. (fda.gov) The same Food and Drug Administration notice drew a limit around that consumer use. Stelo is not intended for people with problematic hypoglycemia, and the agency said users should not make medical decisions from the readings without talking to a healthcare provider. (fda.gov) A1c also has blind spots that help explain the interest in sensor-based metrics. The National Institute of Diabetes and Digestive and Kidney Diseases says hemoglobin variants can produce falsely high or falsely low A1c results, which can lead to over-treatment or under-treatment if the number is read without context. (niddk.nih.gov) That is why the current medical guidance lands on both measures, not one winner. A1c remains the established benchmark for long-term risk, while time in range and time below range give patients and clinicians a same-week map of what food, movement, sleep, stress, and medication changes are actually doing. (diabetesjournals.org)
